investor harm

Bronstein, Gewirtz & Grossman files class action against $ATAR, alleging executives misled investors about manufacturing issues and FDA approval prospects for tabelecleucel.

Class action lawsuit filed against $UPST alleging false statements about Model 22 AI underwriting capabilities and inflated performance metrics.

Class action lawsuit filed against $PSIX alleging materially false statements about data center demand and manufacturing costs. Investors who purchased shares May 2025-March 2026 affected.

Class action lawsuit filed against $BSX alleging material misstatements about U.S. electrophysiology segment growth. Eligible period: July 23, 2025 to February 3, 2026.

Class action lawsuit filed against $ALDYA alleging false statements about reproxalap clinical trial results. Claims inconsistent data, unreliable findings.

Class action lawsuit filed against Coty alleging executives made false statements about growth and profitability between November 2025 and February 2026.

Class action lawsuit filed against $ALIGHT alleging executives made false statements about CEO prospects, capital returns, and revenue targets. Eligible investors had securities between Nov 2024-Feb 2026.

Class action lawsuit filed against $TRIP alleging false statements about regulatory risks from monopolistic practices. Lead plaintiff deadline set for May 11, 2026.

Class action lawsuit filed against Concorde International Group alleging fraudulent stock promotion, social media misinformation, and insider share dumping through offshore accounts.

Class action lawsuit filed against $IBRX over alleged misleading statements regarding Anktiva capabilities between January-March 2026. Lead plaintiff deadline May 26.

Class action lawsuit filed against $EOSE alleging securities fraud over undisclosed production issues, battery downtime, and misleading guidance from November 2025 to February 2026.

Class action lawsuit filed against $MNDY alleging materially false statements about revenue expansion and sales cycle expectations from September 2025 to February 2026.

Class action lawsuit filed against New Era Energy & Digital alleging materially false statements about Texas data centers and New Mexico oil operations.

Lawsuit alleges $BW executives made false statements about business operations and undisclosed conflicts of interest in major contracts.

Class action lawsuit filed against Lufax Holding ($LU) alleging securities fraud, false statements, and inadequate internal controls spanning April 2023 to January 2025.

Class action lawsuit filed against Super Micro Computer alleging undisclosed China sales violating export controls and concealed compliance weaknesses. Lead plaintiff deadline: May 26, 2026.

Class action lawsuit filed against Driven Brands ($DRVN) alleges securities fraud, unreconciled cash balances, and accounting control failures affecting fiscal 2023-2024.

Medpace faces class action lawsuit over allegedly inflated book-to-bill ratio claims during April 2025-February 2026 period; lead plaintiff deadline set for June 5, 2026.

Nektar Therapeutics faces class action suit alleging REZOLVE-AA trial protocol violations. Investors urged to act by May 2026 deadline.

Class action lawsuit filed against Fitness Champs ($FCHL) alleging market manipulation via social media fraud. Investors have until June 16, 2026 to seek lead plaintiff status.